An observational study in Stroke, UULEX and Test-Retest Reliability, sponsored by Karabuk University. Not yet recruiting. Open to participants aged 18 Years to 78 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.
Sponsored by Karabuk University · Observational
This study was designed to determine the test-retest reliability of the Unsupported Upper Limb Exercise Test (UULEX) in individuals with stroke. Motor impairments following stroke, particularly reductions in upper limb muscle strength, motor control, and functional performance, may adversely affect individuals' activities of daily living and functional independence. Therefore, the assessment of upper limb performance using reliable and feasible methods is important for planning and monitoring the rehabilitation process.
The UULEX is an incremental, performance-based, easy-to-administer, and low-cost field test developed to assess upper limb exercise capacity. Although the UULEX has been used in different clinical populations, evidence regarding its test-retest reliability in individuals with stroke is limited. In this study, the UULEX will be administered twice to individuals with stroke at a predetermined interval, and the consistency between the two measurements will be evaluated to determine its test-retest reliability. It is hypothesized that the UULEX will demonstrate high test-retest reliability in individuals with stroke. The findings of this study are expected to provide evidence regarding the reliability of the UULEX as a clinical assessment tool for evaluating upper limb exercise capacity in individuals with stroke.
7,441 studies on the registry are indexed under Stroke; 2,012 are open to participants now.
This study's planned enrollment of 30 is below the median of 160 across 1,729 observational studies indexed under Stroke.
Browse Stroke studies →Karabuk University is the lead sponsor of 131 studies on the registry; 30 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will consist of adults aged 18-78 years with stroke-related hemiplegia who meet the eligibility criteria and voluntarily agree to participate in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Individuals diagnosed with hemiplegia, aged 18-78 years, and willing to participate were included in the study, whereas those with upper extremity or neck pain, cognitive impairment, comorbidities affecting upper extremity and hand function (carpal tunnel syndrome, trigger finger, impingement syndrome, thoracic outlet syndrome, or lateral or medial epicondylitis), or a history of upper extremity surgery were excluded.
Diagnostic Test: Unsupported Upper Limb Exercise Test [UULEX]
The UULEX consists of eight horizontal levels positioned 15 cm apart. Participants are seated facing the chart and raise a 0.2-kg bar from hip level to progressively higher levels at a rate of 30 movements per minute using a metronome. After a 2-min warm-up, the level is increased every minute. Once the highest level is reached, the load is increased by 0.5 kg each minute up to 2 kg. The test continues until symptom limitation or a maximum of 12 min. For reliability assessment, the UULEX will be performed three times using the same standardized protocol. The first two assessments will be conducted on the same day with a 1-h rest interval, and the third will be performed one week later.
Test-Retest Reliability of the Unsupported Upper Limb Exercise Test (UULEX)
Upper limb exercise capacity will be assessed using the Unsupported Upper Limb Exercise Test (UULEX). Participants will perform progressive unsupported upper limb exercise until symptom limitation or the maximum test duration is reached. UULEX performance will be recorded as total test duration (seconds). The test will be performed three times: twice on the same day with a 1-hour interval and once one week later. Test-retest reliability will be determined by comparing UULEX performance across assessments.
Time frame: The UULEX will be administered three times to each participant: the first and second assessments will be performed with a 1-hour rest interval, and the third assessment will be conducted one week later.
No study locations are listed for this record.
Plan to share: No — De-identified individual participant data may be made available from the corresponding author upon reasonable request.
Start is estimated for Oct 2026; primary completion for Nov 2026, 0 months later.
Of 787 non-industry observational studies under Stroke, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 101. This study's planned 0 months is below that.
Counting every sponsor, half of 833 studies reached it within 41 months; a quarter within 18 and three quarters within 92.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Dec 2026 → Nov 2026 and completion Dec 2026 → Nov 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.